

Resource Summary Report

Generated by [RRID](#) on Sep 18, 2026

Global Alzheimers Association Interaction Network

RRID:SCR_023699

Type: Tool

Proper Citation

Global Alzheimers Association Interaction Network (RRID:SCR_023699)

Resource Information

URL: <https://www.gaain.org/>

Proper Citation: Global Alzheimers Association Interaction Network (RRID:SCR_023699)

Description: Open access integrated research platform, which links scientists, shared data, and analysis tools to accelerate Alzheimer's disease research, disease preventions, treatments and cure. Unites diverse and geographically distributed network of data partners to foster cohort discovery, collaboration and sharing. Researchers can discover clinical, genetic, imaging and other data collected across many independent studies.

Abbreviations: GAAIN

Resource Type: data or information resource, disease-related portal, portal, topical portal

Keywords: USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Alzheimer's disease research, disease preventions, treatments and cure, network of data partners, cohort discovery, collaboration and sharing, clinical data, genetic data, imaging data, Alzheimer data discovery,

Related Condition: Alzheimer's disease

Funding: Alzheimer Association

Availability: Free, Freely available

Resource Name: Global Alzheimers Association Interaction Network

Resource ID: SCR_023699

Record Creation Time: 20230621T050216+0000

Record Last Update: 20260912T200041+0000

Ratings and Alerts

No rating or validation information has been found for Global Alzheimers Association Interaction Network.

No alerts have been found for Global Alzheimers Association Interaction Network.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Yuan Z, et al. (2026) Radiomics-enhanced 18F-AV45 PET/MRI for integrative assessment and centiloid estimation of amyloid- β burden in Alzheimer's disease. *European radiology experimental*, 10(1).

Kang SH, et al. (2026) Glymphatic dysfunction links vascular pathology to Alzheimer's biomarkers and cognitive decline. *Alzheimer's research & therapy*, 18(1).

Hu T, et al. (2026) Metabotropic glutamate receptor 5 is associated with plasma GFAP dependent on age. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 22(5), e71473.

Whitmer RA, et al. (2025) Baseline characteristics of the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER): Successful enrollment of a diverse clinical trial cohort at risk for cognitive decline. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 21(6), e70351.

Vila-Castelar C, et al. (2025) Sex/gender effects of glial reactivity on preclinical Alzheimer's disease pathology. *Molecular psychiatry*, 30(4), 1430.

Kesler SR, et al. (2025) Temporal dysregulation of PPARG-PRKAG2 co-expression in gray matter: Implications for cognitive decline and intervention targets in type 2 diabetes. *Research square*.

Janve VA, et al. (2025) Blood gene expression network expression strongly relates to brain amyloid burden. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 21(12), e70982.

Younes K, et al. (2025) Amyloid PET predicts longitudinal functional and cognitive trajectories in a heterogeneous cohort. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 21(3), e70075.

Kim JP, et al. (2025) Cross-ancestry genome-wide association study identifies implications of SORL1 in cerebral beta-amyloid deposition. *Nature communications*, 16(1), 3150.

Chun MY, et al. (2025) Distinct Characteristics of Suspected Non-Alzheimer Pathophysiology in Relation to Cognitive Status and Cerebrovascular Burden. *Clinical nuclear medicine*, 50(5), 368.

Yim S, et al. (2025) CT-derived brain volumes and plasma p-Tau217 for risk stratification of amyloid positivity in early-stage Alzheimer's disease. *Alzheimer's research & therapy*, 17(1), 233.

Cody KA, et al. (2025) Comparison of amyloid PET acquired through standardized and unstandardized protocols. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 21(9), e70697.

Kim BH, et al. (2025) Mapping Alzheimer's disease pathology using free water through integrated analysis of plasma biomarkers, microstructural DTI metrics, and macrostructural MRI measures. *Scientific reports*, 15(1), 30702.

Dorfschmidt L, et al. (2025) Charting structural brain asymmetry across the human lifespan. *bioRxiv : the preprint server for biology*.

Coupé P, et al. (2025) petBrain: a new pipeline for amyloid, Tau tangles and neurodegeneration quantification using PET and MRI. *Alzheimer's research & therapy*, 17(1), 209.

Yun J, et al. (2025) Integrative analysis of AT classification, plasma biomarkers, and cognitive trajectories across diverse dementia syndromes. *Scientific reports*, 16(1), 610.

Akinci M, et al. (2025) Physical activity changes during midlife link to brain integrity and amyloid burden. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 21(5), e70007.

Kac PR, et al. (2025) Plasma p-tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 21(4), e70172.

Sosa AL, et al. (2024) Advancements in dementia research, diagnostics, and care in Latin America: Highlights from the 2023 Alzheimer's Association International conference satellite symposium in Mexico City. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 20(7), 5009.

Lao P, et al. (2024) Cerebrovascular disease emerges with age and Alzheimer's disease in adults with Down syndrome. *Scientific reports*, 14(1), 12334.